



The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation

Andrew P. McGovern^{1,2} · Nick J. Thomas^{1,2} · Sebastian J. Vollmer^{3,4} · Andrew T. Hattersley^{1,2} · Bilal A. Mateen^{3,5} · John M. Dennis¹

Received: 10 January 2021 / Accepted: 25 January 2021
© The Author(s) 2021

Keywords COVID-19 · Death · Diabetes · Vaccination

Abbreviation

COVID-19 Coronavirus disease-2019

To the Editor: Diabetes has consistently been shown to independently increase the risk of poor coronavirus disease-2019 (COVID-19) outcomes [1–3]. Rather than a simple additive effect of diabetes and age-related risk, recent large studies suggest a more complex relationship, with a disproportionately higher excess relative mortality risk in younger people with diabetes compared with older people with diabetes [1, 3, 4]. Better understanding of the interaction between age and diabetes in the context of COVID-19 will further inform the complex prioritisation decisions around COVID-19 vaccination [5].

To explore this relationship, we triangulated the evidence on heterogeneity of diabetes effect by age on COVID-19 mortality from large population-based and critical care-based studies. Two UK population-based studies (OpenSAFELY [$n = 17,278,392$; 8.8% with diabetes] and QCOVID [$n = 6,083,102$; 7.0% with diabetes]) have previously reported adjusted age-specific hazard ratios for COVID-19-related mortality risk associated with diabetes [1, 4]. OpenSAFELY

reported these stratified by recent HbA_{1c} measurements as recorded in primary care ($< \geq 58$ mmol/mol [$< \geq 7.5\%$] or not available), but not by diabetes type. QCOVID reported age-specific hazard ratios for type 2 diabetes by sex, but did not report age-specific values for type 1 diabetes (see electronic supplementary material [ESM] [Methods](#)). The overall 90-day COVID-19-related mortality rate was 0.06% in OpenSAFELY (study period: 1 February 2020–6 May 2020) and the 97-day COVID-19-related mortality rate was 0.07% in QCOVID (derivation cohort study period: 24 January 2020–30 April 2020).

Building on our previous analysis in the critical care setting [3], we also examined adjusted age-specific hazard ratios associated with type 2 diabetes in people with severe COVID-19 using the COVID-19 Hospitalisation in England Surveillance System (CHESS) cohort ($n = 19,256$ individuals admitted to critical care in England; 18.3% with type 2 diabetes; see ESM [Methods](#)). In this cohort, the 30-day in-hospital mortality rate was 26.4% (see ESM Table 1 for age-stratified mortality rates).

To aid interpretability of our findings, based on the work of Spiegelhalter [6, 7], we translated hazard ratio estimates into ‘COVID-age’, which represents the additional years of COVID-19 mortality risk added to an individual’s chronological age if diabetes is present. Full details of our approach are provided in the ESM [Methods](#). The study was reviewed and approved by the Warwick BSREC (BSREC 119/19-20).

The additional COVID-19 mortality risk associated with diabetes is, in terms of COVID-age, markedly higher in younger than older people (Fig. 1). This reflects the higher relative risk of COVID-19-related mortality associated with diabetes in younger age groups (hazard ratios for diabetes > 5 in adults under 50 years of age in population-based studies). Population-based and critical care-based estimates are similar, despite differences in setting, time period and adjustments for

✉ John M. Dennis
j.dennis@exeter.ac.uk

¹ Institute of Biomedical & Clinical Science, University of Exeter Medical School, Royal Devon & Exeter Hospital, Exeter, UK

² Diabetes and Endocrinology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK

³ Alan Turing Institute, London, UK

⁴ Department of Statistics, University of Warwick, Coventry, UK

⁵ Institute of Health Informatics, University College London, London, UK




Fig. 1 The additional years of COVID-19 mortality risk added to an individual's chronological age if diabetes is present ('COVID-age') compared with actual age (dotted black line) in people aged 30–90 years. Data are from two large UK population-based studies (OpenSAFELY [$n=17,278,392$] and QCOVID [$n=6,083,102$]) and a national database of critical care patients in England (COVID-19 Hospitalisation in England Surveillance System [CHES] cohort [$n=19,256$]). Underlying data are reported in ESM Table 2. ^aCOVID-age estimates are from QCOVID data

confounders between studies. For a person aged 40 years with diabetes, additional mortality risk is equivalent to around 20 years of chronological age, meaning that mortality risk is similar to that of a 60-year-old person without diabetes. For a person aged 70 years with diabetes, the additional mortality risk from diabetes is equivalent to an additional 8 years of age, so their COVID-age is 78 years (based on QCOVID data).

Clearly, considering only age and diabetes status when assessing COVID-19-associated risks (both mortality and in general) is an oversimplification. Multiple additional factors, including BMI, diabetes duration, glycaemic control, diabetes type and existing complications are known to further modify individual COVID-19 risk [8, 9]. Whilst patient-level risk incorporating these multiple factors can be calculated [10] (and is preferable for informing individuals of their COVID-19 risk), this is not practical for population-level vaccine roll-out. The time-critical nature of population COVID-19 vaccination necessitates pragmatic group-level prioritisation, which is the approach initiated by governments thus far [11, 12].

Whilst the absolute risk of COVID-19-related mortality in younger people with diabetes is still not as high as that of the elderly, vaccine prioritisation approaches should not simply consider absolute mortality risk. Younger people are disproportionately impacted in terms of life years lost and are of working age, which puts them at potentially higher risk of

exposure. These factors should be considered, alongside the excess relative COVID-19 mortality risk in younger people with diabetes, to ensure that they are appropriately prioritised for vaccination.

Supplementary Information The online version (<https://doi.org/10.1007/s00125-021-05404-8>) contains peer-reviewed but unedited supplementary material.

Acknowledgements JMD is supported by an Independent Fellowship funded by Research England's Expanding Excellence in England (E3) fund. SJV and BAM are supported by The Alan Turing Institute (EPSRC grant EP/N510129/1). SJV is supported by the University of Warwick IAA funding. ATH is an NIHR Senior Investigator and a Wellcome Trust Senior Investigator (098395/Z/12/Z). JMD, NJT, ATH and APM are supported by the NIHR Exeter Clinical Research Facility. We thank Public Health England for providing access to CHES data to the Warwick Research Group and M. Keeling (University of Warwick, Warwick, UK) for his support and establishing data access. Sponsorship for the study was provided by the University of Warwick (SOC.28/19-20).

Data availability CHES data cannot be shared publicly as it was collected by Public Health England as part of their statutory responsibilities, which allows them to process patient confidential data without explicit patient consent. Data utilised in this study were made available through an agreement between the University of Warwick and Public Health England. Individual requests for access to CHES data are considered directly by Public Health England (contact via covid19surv@phe.gov.uk).

Funding This study was supported by Diabetes UK (20/0006220). The funder had no role in the analysis or reporting of results.

Authors' relationships and activities APM declares previous research funding from Eli Lilly and Company, Pfizer and AstraZeneca. SJV declares funding from IQVIA. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement JMD, BAM, NJT, APM and SJV designed the study. JMD drafted code on dummy data. SJV adapted and extended the code and executed on CHES. JMD, BAM, APM and SJV drafted the article. All authors provided support for the analysis and interpretation of results, critically revised the article and approved the final article. JMD, BAM and SJV take responsibility for the integrity of the data and the accuracy of the data analysis.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Williamson EJ, Walker AJ, Bhaskaran K et al (2020) Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 584(7821):430–436. <https://doi.org/10.1038/s41586-020-2521-4>
- Barron E, Bakhai C, Kar P et al (2020) Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol* 8(10):813–822. [https://doi.org/10.1016/S2213-8587\(20\)30272-2](https://doi.org/10.1016/S2213-8587(20)30272-2)
- Dennis JM, Mateen BA, Sonabend R et al (2020) Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England, March–July 2020. *Diabetes Care* 44(1):50–57. <https://doi.org/10.2337/dc20-1444>
- Clift AK, Coupland CAC, Keogh RH et al (2020) Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. *BMJ* 371:m3731. <https://doi.org/10.1136/bmj.m3731>
- The Lancet Diabetes & Endocrinology (2021) Coronavirus vaccine? Join the queue. *Lancet Diabetes Endocrinol* 9(1):1. [https://doi.org/10.1016/S2213-8587\(20\)30409-5](https://doi.org/10.1016/S2213-8587(20)30409-5)
- Spiegelhalter D (2020) Use of “normal” risk to improve understanding of dangers of covid-19. *BMJ* 370:m3259. <https://doi.org/10.1136/bmj.m3259>
- Spiegelhalter D (2016) How old are you, really? Communicating chronic risk through ‘effective age’ of your body and organs. *BMC Med Inform Decis Mak* 16(1):104. <https://doi.org/10.1186/s12911-016-0342-z>
- Holman N, Knighton P, Kar P et al (2020) Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. *Lancet Diabetes Endocrinol* 8(10):823–833. [https://doi.org/10.1016/S2213-8587\(20\)30271-0](https://doi.org/10.1016/S2213-8587(20)30271-0)
- Cariou B, Hadjadj S, Wargny M et al (2020) Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. *Diabetologia* 63(8):1500–1515. <https://doi.org/10.1007/s00125-020-05180-x>
- McGurnaghan SJ, Weir A, Bishop J et al (2021) Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. *Lancet Diabetes Endocrinol* 9(2):82–93. [https://doi.org/10.1016/S2213-8587\(20\)30405-8](https://doi.org/10.1016/S2213-8587(20)30405-8)
- Public Health England (2021) COVID-19 vaccination first phase priority groups. Available from: www.gov.uk/government/publications/covid-19-vaccination-care-home-and-healthcare-settings-posters/covid-19-vaccination-first-phase-priority-groups. Accessed: 6 January 2021
- Centers for Disease Control and Prevention (2021) When Vaccine is Limited, Who Should Get Vaccinated First? Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations.html>. Accessed: 6 January 2021

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.